Online inquiry

IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12129MR)

This product GTTS-WQ12129MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FOLR1 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000802.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2348
UniProt ID P15328
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12129MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15842MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ822MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11667MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ1332MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ5198MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ5417MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ2246MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ10725MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-281
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW